Polymer synthesis, inorganic nanoparticle synthesis, MRI, and Liquid metal
Xumin Huang focuses on developing organic/inorganic nanohybrids as next-generation molecular imaging probes.
Inspired by advanced nanotechnology, next-generation theranostic agents based on RAFT polymer attract our attention. Despite extensive high-impact works, there is still lacking a deep understanding of nanoparticles, especially the interaction of their organic components and inorganic components. My PhD projects will focus on understanding the interaction within the nanoparticles, and developing high efficient theranostic agents.
2015-2019, Soochow University, China. Bachelor of Science in Pharmacy.
2019-2022, The University of Queensland, Australia. Master of Philosophy.
2021-2022, The University of Queensland, Australia. Research Assistant.
2022-present, The University of Queensland, Australia. PhD Candidate.
Key Publications
Huang, X.; Xu, T.; Shen, A.; Davis, T. P.; Qiao, R.; Tang, S-Y.; Engineering Polymers via Understanding the Effect of Anchoring Groups for Highly Stable Liquid Metal Nanoparticles. ACS Appl. Nano Mater. 2022, https://doi.org/10.1021/acsanm.1c04138
Huang, X.; Hu, J.; Li, Y.; Xin, F.; Qiao, R.; Davis, T. P., “Engineering Organic/Inorganic Nanohybrids through RAFT Polymerization for Biomedical Applications.” Biomacromolecules 2019, 20, 4243-4257.
Qiao, R.; Huang, X.; Qin, Y.; Li, Y.; Davis, T. P.; Hagemeyer, C. E.; Gao, M., “Recent Advances in Molecular Imaging of Atherosclerotic Plaques and Thrombosis.” Nanoscale 2020, 12, 8040-8064.
Xu, X.; Huang, X.; Chang, Y.; Yu, Y.; Zhao, J.; Isahak, N.; Teng, J.; Qiao, R.; Peng, H.; Zhao, C.; Davis, T. P.; Fu, C.; Whittaker, A. K., “Antifouling Surfaces Enabled by Surface Grafting of Highly Hydrophilic Sulfoxide Polymer Brushes.” Biomacromolecules 2021, 22, 330-339.
Hu, J.; Fang, Y.; Huang, X.; Qiao, R.; Quinn, J.; Davis, T. P., “Engineering Macromolecular Nanocarriers for Delivery of Gaseous Signaling Molecules.” Adv. Drug Delivery Rev. 2021, 179, 114005
| Featured projects | Duration |
|---|---|
| Biocompatible Gadolinium-free contrast agents for molecular targeted MR imaging | 2021–2026 |